GMTX News and Press, Gemini Therapeutics Inc. From 05/13/21

Gemini Therapeutics (GMTX): Q1 GAAP EPS of -$0.59 misses by $0.25.At March 31, 2021, Gemini held $185.0 million in cash, $9.2 million of principal outstanding debt and 43.0 million shares outstanding.Press Release For further details see: Gemini Therapeutics EPS misses by $0.25

Gemini Therapeutics (GMTX) announces the completion of enrollment in its Phase 2a trial testing GEM103 as a potential add-on therapy for certain patients suffering from wet Age-related macular degeneration ((AMD)), a progressive retinal disease.The trial looks at treating wet AMD pa...

- Fast Track Designation for GEM103 in dry AMD granted January 2021 - GEM103 Phase 2a study in geographic atrophy data on track for June 2021 - GEM103 Phase 2a as a possible add-on therapy for patients with wet AMD at risk for macular atrophy completed enrollment, with...

-Topline data expected in late 2021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phas...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of ...

− GEM103 demonstrates anti-angiogenic activity in a mouse model of laser-induced choroidal neovascularization (CNV) Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-relat...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini’s Chief Financial Office...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s C...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Gemini Therapeutics (GMTX): FY net loss of $40.8M compared to $41.4M last year.Cash position of approximately $200M.Press Release For further details see: Gemini Therapeutics reports FY results